Clinical trial · Interventional
Chemotherapy in Treating Patients With Recurrent Malignant Glioma
Phase I Treatment of Adults With Primary Malignant Glioma With Topotecan (NSC #609699) Plus BCNU (NSC #409962)
NCT00002986CI-TRIAL-00009500completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of topotecan plus carmustine in patients with recurrent primary malignant glioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain and Central Nervous System Tumors | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carmustine | Drug | Carmustine | ALIAS |
| topotecan hydrochloride | Drug | Topotecan | ALIAS |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically proven recurrent primary malignant glioma * Measurable recurrent or residual primary central nervous system neoplasm confirmed by MRI PATIENT CHARACTERISTICS: Age: * 18 and over Performance Status: * Karnofsky at least 60% Hematopoietic: * Hematocrit greater than 29% * ANC greater than 1,500/mm\^3 * Platelet count greater than 125,000/mm\^3 Hepatic: * SGOT less than 1.5 times upper limit of normal (ULN) * Bilirubin less than 1.5 times ULN Renal: * Creatinine less than 1.5 mg/dL * BUN less than 25 mg/dL Other: * Not pregnant * Effective contraceptive method must be used for the duration of the study PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy within 6 weeks of study * No prior topotecan or carmustine treatment failure * No more than 1 prior chemotherapy regimen Endocrine therapy: * Patients taking corticosteroids must be on stable dose for at least 2 weeks prior to study and the dose should not escalate over entry level Radiotherapy: * No prior radiotherapy within 6 weeks of study Surgery: * No prior surgical resection within 3 weeks of study Other: * No concurrent medication that may interfere with study results
References
Publications (0)
Data not yet available
No reference posted for this study.